Roche: Reports Positive Phase II Results For Dual GLP-1/GIP Agonist Enicepatide In Type 2 Diabetes And Overweight Or Obesity
Enicepatide 24mg Reduced HbA1c By 4.13% At 48 Weeks In Poorly Controlled Patients - 90% Of Enicepatide 24mg Patients Achieved HbA1c 6.5% At 48 Weeks; 62% Achieved Normoglycaemia - Plans Phase III Glycaemic-Control And Cardiovascular Outcomes Trials In H1 2027 - Safety Profile Consistent With Incretin Class; No New Safe